Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

FDA
News

FDA Site Shows Approval For MediWound’s NexoBrid

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761192

byBenzinga Newsdesk

December 29, 2022

1 minute read

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761192

Dash Rallies 15% As Dogecoin ‘Relative’ Shows Positive Movement

By Mehab Qureshi

Today, 12:44 PM

Dash (CRYPTO: DASH) surged over 15.64% on Wednesday, topping CoinMarketCap’s gainers of the day.

$DOGE

Morgan Stanley Maintains Underweight on Lithia Motors, Lowers Price Target to $300

By Benzinga Newsdesk

Today, 12:44 PM

Morgan Stanley maintains Lithia Motors (NYSE:LAD) with a Underweight and lowers the price target from $303 to $300.

LAD

Piper Sandler Maintains Overweight on Wells Fargo, Raises Price Target to $49

By Benzinga Newsdesk

Today, 12:44 PM

Piper Sandler analyst Scott Siefers maintains Wells Fargo (NYSE:WFC) with a Overweight and raises the price target from $48 to $49.

WFC

GlaxoSmithKline Reports Phase 3 Efficacy, Safety Data For Daprodustat In Patients With Anaemia Due To Kidney Disease

By Benzinga Newsdesk

Today, 12:44 PM

- Late-breaking data from the daprodustat ASCEND-ND and ASCEND-D trials at the American Society of Nephrology's Kidney Week 2021 confirms the potential for a new oral treatment for patients with anaemia due to

GSK

FDA Site Shows Approval For MediWound’s NexoBrid

Related Posts

Dash Rallies 15% As Dogecoin ‘Relative’ Shows Positive Movement

Morgan Stanley Maintains Underweight on Lithia Motors, Lowers Price Target to $300

Piper Sandler Maintains Overweight on Wells Fargo, Raises Price Target to $49

GlaxoSmithKline Reports Phase 3 Efficacy, Safety Data For Daprodustat In Patients With Anaemia Due To Kidney Disease